Hareket Bozukluğunda Acil Durumlara Klinik Yaklaşım
Özet
Hareket bozukluğu acilleri, istemsiz hareketler veya istemli hareketleri sürdürmede zorlanma ile karakterize, saatler veya günler içinde gelişen ve hızlı müdahale edilmediğinde yüksek morbidite ile mortalite riski taşıyan klinik durumlardır. Bu aciller arasında en sık karşılaşılanlardan biri olan akut parkinsonizm; genellikle tipik/atipik nöroleptikler, antiemetikler veya karbonmonoksit gibi toksinlere maruziyet ve viral enfeksiyonlar sonucu, simetrik bradikinezi ve rijidite ile akut olarak ortaya çıkar. Dopamin reseptör bloke edici ilaçların kullanımı veya dopamin agonistlerinin ani kesilmesiyle tetiklenen nöroleptik malign sendrom (NMS) ise ağır rijidite, yüksek ateş, bilinç değişiklikleri ve otonomik instabilite ile seyreden, hayatı tehdit eden ciddi bir reaksiyondur. Benzer şekilde, serotonerjik ajanların tek başına veya kombine kullanımı neticesinde gelişen serotonin sendromu (SS); mental durum değişiklikleri, otonomik hiperaktivite ve nöromusküler hiperaktivite triadı ile kendini gösterir. Yaşamı tehdit eden bir diğer tablo olan status distonikus, travma, enfeksiyon veya ilaç değişiklikleriyle tetiklenen şiddetli, jeneralize ve tedaviye dirençli distoni atakları ve ağrılı kontraksiyonlarla karakterizedir. Son olarak, akut kore-hemiballismus ise genellikle bazal ganglionları veya subtalamik nükleusu etkileyen akut vasküler lezyonlar ya da metabolik bozukluklar nedeniyle gelişen, geniş amplitüdlü istemsiz hareketleri kapsar. Bu hareket bozukluğu acillerinin yönetiminde erken teşhis, tetikleyici ajanların hemen kesilmesi, multidisipliner yoğun bakım takibi ve semptoma yönelik acil farmakolojik tedaviler hayati önem taşımaktadır.
Movement disorder emergencies are acute clinical conditions characterized by involuntary movements or difficulty in sustaining voluntary movements that develop within hours or days, carrying high morbidity and mortality risks if not promptly managed. Among the most common of these, acute parkinsonism manifests acutely with symmetric bradykinesia and rigidity, typically triggered by the use of typical/atypical neuroleptics, antiemetics, exposure to toxins like carbon monoxide, or viral infections. Neuroleptic malignant syndrome (NMS), induced by dopamine receptor-blocking drugs or the abrupt withdrawal of dopamine agonists, is a life-threatening reaction presenting with severe rigidity, high fever, altered mental status, and autonomic instability. Similarly, serotonin syndrome (SS), resulting from the single or combined use of serotonergic agents, is characterized by a clinical triad of mental status changes, autonomic hyperactivity, and neuromuscular hyperactivity. Another life-threatening condition, status dystonicus, features severe, generalized, and treatment-resistant dystonic storms and painful contractions often triggered by trauma, infection, or medication changes. Lastly, acute chorea-hemiballismus involves large-amplitude involuntary movements usually caused by acute vascular lesions affecting the basal ganglia or subthalamic nucleus, or by metabolic disturbances. In the management of all these movement disorder emergencies, early recognition, immediate discontinuation of the offending agents, multidisciplinary intensive care monitoring, and symptom-specific urgent pharmacological interventions are of vital importance.
Referanslar
Poston kl, Fruncht SJ.Movement disorder emergencies.J Neurol 2008;255(Suppl.4):2-13
Hassin-Baer S, Sirota P,Korczyn AD et al. Clinical characteristic of neurolopetıc-induced parkinsonism. J Nerual Transm 2001;108(11):1299-1308
BhattMG, EliasMA,Mankodi AK. Acute and reversible parkinsonism due to organophosphate pesticide intoxication: five cases.Neurology 1999;52:1467–1471.
Robottom BJ, Weiner WJ, Factor SA. Movement disorders emergencies part 1:hypokinetic disorders. Arch Neurol 2011;68:567–72.
Hubble JP. Drug-Induced Parkinsonism. In: Watts RL, Koller WC,editors. Movement Disorders Neurological Principles & Practice (second edition). New York: McGraw-Hill:2004.p.395-9
Jankovic J, Shannon KM. Movement Disorders. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J, edıtors. Clinical Practice Volume II (Fourth edition). Philedelphia :Butterworth-Heinemann:2008.p. 2081-122
Rail D, Scholtz C, Swash M. Post-encephalitic parkinsonism: current experience. J Neurol Neurosurg Psychiatry 1981;44:670 676.
Ogata A, Tashiro K, Pradhan S. Parkinsonism due to predominant involvement of substantia nigra in Japanese encephalitis. Neurology 1999;53:1781–1786.
Less AJ.Secondaary Parkinson’s Syndrome. In :Jankovicc J,Tolosa E, editors. Parkinson’s Disease &Movement Disorders (fifth edition). Philedelphia :Lippincott Wiliams&Wilkins;2007.p.213-22.
Zijlmas JC, Daniel SE, Hughes AJ, Revesz T, Lees AJ. Clinicopathological investigation of vasculer parkinsonism, including clinical criteria for diagnosis. MOv. Didord 2004;19(6):630-40.
Schramm A, Grunwald S, Lorenz R, Classen J, Naumann M.Paarkinsonism due to bilateral basal ganglia lesions following mastocytosis-induced hypoxia. J Neurol 2004:251(10):1270-2.
Choi IS,Cheon HY.Deloyed movement disorders after carbon monoxide poisoning. Eur Neurol 1999; 42:141-4
Frucht SJ. Treatment of movement disorder emergencies. Neurotherapeutics. 2014 Jan;11(1):208-12. doi: 10.1007/s13311-013-0240-3.
Sacks O. Awakenings. Harper Perennial, New York, 1990.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision. Washington, DC, American Association, 2000.
Peiris DTS, Kuruppuarachchi KALA,Weresena LP, et al:Neuroleptic malignant syndrome without fever: A report of three cases. J Neurol Neurosurg Psychiatry 2000;69:277-278
Kellam AMP. The neuroleptic malignant syndome, so-called:a survey of the World literatüre Br J psychiatry 1987;150:752-759
Shalev A, Hermesh H, Munitz H. Moratility from neuroleptic malignanat syndrome. J Clin Psychiatry 1989;50:18-25
Schönfeldt-Lecuona C, Kuhlwilm L, Cronemeyer M, Neu P, Connemann BJ, Gahr M, Sartorius A, Mühlbauer V. Treatment of the Neuroleptic Malignant Syndrome in International Therapy Guidelines: A Comparative Analysis. Pharmacopsychiatry. 2020 Mar;53(2):51-59. doi: 10.1055/a-1046-1044.
Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q. 2001 Winter;72(4):325-36. doi: 10.1023/a:1010389215197.
Wang HC, Hsich H (2001) Treatment of neuroleptic malignant syndrome with subcutaneous apomophine monotherapy. Mov Disord 16:765-767
Ener RA, Meglathery SB, Van Decker WA, Gallagher RM. Serotonin syndrome and other serotonergic disorders. Pain Med 2003;4:63-74
Miyasaki JM, Lang AE. Treatment of drug-induced movement disorders. In: Kurlan R (Ed). Treatment of movement disorders. Philadelphia: Lippincott; 1995:429-474.
Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005 Oct;95(4):434-41. doi: 10.1093/bja/aei210.
Bronstein AC, Spyker DA, Cantilena LR Jr., Rumack BH, Dart RC. 2011 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol (Phila) 2012; 50:911.
Volpi-Abadie J, Kaye AM, Kaye AD.. Serotonin syndrome. The Ochsner Journal 2013; 13:533-540.
Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997;17:208–221.
Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003;96:635-642.
Ables AZ, Nagubilli R. Prevention, recognition, and management of serotonin syndrome. Am Fam Physician 2010;81:1139-1142.
Munhoz RP, Moscovich M, Araujo PD, Teive HA. Movement disorders emergencies: a review. Arq Neuropsiquiatr. 2012 Jun;70(6):453-61. doi: 10.1590/s0004-282x2012000600013.
Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998;16:615–619.
Jankovic J, Penn AS. Severe dystonia and myoglobinuria. Neurology 1982;32:1195-1197
Mariotti P, Fasano A, Contrarino MF, et al. Management of status dystonicus: our experience and review of the literature. Mov Disord 2007;22:963-968.
Manji H, Howard RS, Miller DH, et al. Status dystonicus: the syndrome and its management. Brain 1998;121:243-252
Teive HA, Sá DS, Grande CV, Antoniuk A, Werneck LC. Bilateral pallidotomy for generalized dystonia. Arq Neuropsiquiatr 2001; 59:353-357.
Dewey RB, Jankovic J. Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol 1989;46:862-867.
Lang AE. Persistent hemiballismus with lesions outside the subthalamic nucleus. Can J Neurol Sci 1985;12:125-128.
